Avidity Expands Cardiovascular Collaboration with Bristol for up to Five Targets

 Avidity to receive $100 million up front with the potential to receive up to $2.2 billion in milestone payments and up to low double-digit royalties

Global licensing and research collaboration to focus on discovery, development and commercialization of up to five cardiovascular targets leveraging Avidity's proprietary AOC platform technology

https://www.prnewswire.com/news-releases/avidity-biosciences-announces-expansion-of-cardiovascular-collaboration-with-bristol-myers-squibb-for-up-to-five-targets-utilizing-aviditys-proprietary-aoc-platform-technology-301998479.html